Navigation Links
Circassia's Hay Fever Treatment Improves Patients' Allergy Symptoms in Phase II Clinical Trial
Date:9/27/2011

OXFORD, England, September 27, 2011 /PRNewswire/ --

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced positive phase II clinical results showing that its ToleroMune® hay fever vaccine substantially improved patients' allergy symptoms compared with those on placebo.  The treatment was extremely well tolerated.  

During the randomised, double-blind, placebo-controlled phase II study conducted in 50 hay fever sufferers in Quebec, Canada, patients received four doses from one of five different treatment regimes over a 12-week period.  Five weeks later, investigators tested the patients' skin and eye responses to grass pollen.  The results show that the treatment reduced allergic symptoms in patients' eyes by up to 30% more than placebo.  In addition, the therapy improved early and late skin reactions by up to 54% and 19% above placebo respectively.  The ToleroMune T-cell vaccine had a similar safety profile to placebo.

Following these results, Circassia has initiated the final phase II trial of its hay fever treatment.  The double-blind, placebo-controlled study is underway in Kingston, Canada in 280 volunteers, and will assess the effectiveness of the ToleroMune T-cell vaccine at improving patients' nasal symptoms and eye responses when exposed to grass pollen in an exposure chamber.  

"Achieving these clinical results is particularly encouraging as hay fever is an extremely common allergy, which can have a major impact on sufferers," said Steve Harris, Circassia's CEO.  "Many current therapies provide short-term symptom relief only, while traditional immunotherapies can require specialist treatment over several years to address the underlying disease.  Circassia's latest results follow earlier successful studies in a range of different allergies.  Our clinical data show that Circassia's T-cell vaccines have the p
'/>"/>

SOURCE Circassia
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Lactobacillus Beverage Confirmed to Reduce Fever Brought on by Acute Gastroenteritis Caused by Norovirus Infection
2. University of Utah and Navigen Pharmaceuticals Announce a New Government Contract to Advance Slit2N for the Treatment of Hemorrhagic Fever and Anthrax Exposure
3. Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV™ (acetaminophen) injection for the Management of Pain and Fever
4. Newly Published Caldolor® Clinical Data Demonstrates 77% Reduction in Fever in Hospitalized Patients
5. Corgenix and Tulane Announce Award of Additional NIH Contract to Expand Lassa Fever Research Towards Development of Vaccines and Improved Therapeutic Agents
6. Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus
7. Fincor (FINC) Makes a Share Transfer and Enters the Market With ACTRx a New Malaria and Dengue Fever Treatment
8. The New Face of Personalized Medicine: Targeting Disease Diagnostics and Treatments with Big Data Analytics: October 6, 2011, 1 PM EDT, Webinar
9. Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T
10. TWi Biotechnology Successfully Completes Patient Recruitment for Phase IIb Trial of AC-201 for the Treatment of Type II Diabetes
11. New Study Finds Cord Blood-derived Stem Cell Treatments Improve Ataxia Patients Functionality and Quality of Life
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... IRVING, Texas , May 29, 2015 /PRNewswire/ ... company focused on fulfilling the promise of precision ... five studies that demonstrate the clinical utility of ... comprehensive tumor profiling service, in helping to identify ... aggressive tumors. In each of the studies, results ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 Seoul ... leader in LED technology, on May 28th announced ... market share by strengthening its high efficient and ... application , Since 2011 Seoul Semiconductor has developed ... lighting market and has supplied LEDs for headlamps ...
(Date:5/28/2015)... 2015  Quest Diagnostics Incorporated (NYSE: DGX ), ... that it is scheduled to speak at the Jefferies ... Rusckowski , the company,s President and CEO, will discuss ... presentation is scheduled for Tuesday, June 2, 2015 at ... be webcast live during the conference and will be ...
(Date:5/28/2015)... Research and Markets( http://www.researchandmarkets.com/research/6cg3zw/cell_therapy ) has ... "Cell Therapy - Technologies, Markets and Companies" ... describes and evaluates cell therapy technologies and methods, ... role in the practice of medicine. Hematopoietic stem ... marrow transplants. Role of cells in drug discovery ...
Breaking Biology Technology:Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 2Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 3Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 4Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 5Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 6Seoul Semiconductor Increases the Global Automotive LED Market Share with its High Efficient and Reliable LEDs for Automotive Lightings 2Quest Diagnostics to Speak at the Jefferies 2015 Global Healthcare Conference 2Global Cell Therapy Market 2015-2020 - Technologies, Markets and Companies 2
... Mass., Oct. 1 Based on the clinical ... today announced,that the company has expanded its executive ... MA. "The move to Massachusetts,allows us to consolidate ... Geoff Pardo. "It also gives us access to ...
... CITY, Oct. 1, /PRNewswire-FirstCall/ - AEterna Zentaris ... global biopharmaceutical company focused on,endocrine therapy and ... for the Company,s second efficacy trial of ... (BPH), a non-cancerous enlargement of the,prostate, with ...
... DUBLIN, Ireland, October 1 Shire Limited,(LSE: SHP, NASDAQ: ... approval by shareholders at the Annual General,Meeting on September ... Shire,plc with effect from today., Shire plc,s ticker ... ISIN numbers of the Company,s Ordinary shares and American ...
Cached Biology Technology:Facet Solutions Establishes Corporate Headquarters and Expands Executive Team 2AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia 2AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia 3AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia 4
(Date:5/28/2015)... May 28, 2015 Industry analyst firm ... new report titled "Markets for Self-Healing Materials: 2015-2022." According ... capsule and vascular systems, biomaterials, relevant shape memory ... around $2.7 billion by 2020. The ... coverage of smart materials. Other recent n-tech reports have ...
(Date:5/26/2015)... 2015 Research and Markets ... the "Saudi Arabia Biometric Systems Market Forecast ... ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The biometric systems market ... projected to grow at over 22% CAGR through ... to the surging demand for better biometric technologies ...
(Date:5/22/2015)... , May 22, 2015  NXT-ID, Inc. (NASDAQ: ... 1st, it will be ending its promotional pricing and making ... Laurence Savin , Head of Marketing said, ... promotional pricing until the end of May. To get your ... and when we open the store on June 1, you,ll ...
Breaking Biology News(10 mins):The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Saudi Arabia Biometric Systems Market Forecast and Opportunities, 2020 with Morpho Safran, ZK Technlogy, and Suprema Dominating 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3
... 18 October 2010, Singapore A total of 15 world ... in their respective fields at the 6th Decade of the ... 20 October 2010. Jointly organised by A*STAR,s Institute of ... (DRTech) and NUS,s Temasek Laboratories, it is the first such ...
... -- Harvard University neurobiologists have created mice that can "smell" ... better understand the neural basis of olfaction. The work, ... has implications for the future study of smell and of ... study with traditional methods. "It makes intuitive sense to ...
... 22 Lockheed Martin (NYSE: LMT ) and ... system that has potential to transform how law enforcement, homeland ... their missions. The prototype, called Rap I.D .™, ... special session on Rapid DNA. The day-long session is ...
Cached Biology News:Singapore hosts first 'Decade of the Mind' conference in Asia 2Singapore hosts first 'Decade of the Mind' conference in Asia 3Mice that 'smell' light could help us better understand olfaction 2Lockheed Martin and ZyGEM Accelerate DNA Identification for Law Enforcement, Homeland Security and Defense Communities 2Lockheed Martin and ZyGEM Accelerate DNA Identification for Law Enforcement, Homeland Security and Defense Communities 3
... Each glass slide in this set ... antibodies in triplicate, for a total ... house-keeping proteins as internal control. Antibodies ... as angiogenesis, apoptosis, cell cycle progression, ...
...
...
... T7 Phage Capture Plate is a 96-well ELISA-compatible ... the T7 Tail Fiber Monoclonal Antibody is immobilized ... The antibody specifically recognizes the tail fiber protein ... has a capacity of 10 9 phage ...
Biology Products: